AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial

BACKGROUND: Inhibiting vascular endothelial growth factor (VEGF) function can improve the efficacy of immunotherapy by modulating the tumor immune microenvironment. AK112 is the first-in-class humanized IgG1 bispecific antibody targeting programmed death-1 (PD-1) and VEGF. This study aimed to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yuanyuan, Chen, Gang, Chen, Jianhua, Zhuang, Li, Du, Yingying, Yu, Qitao, Zhuang, Wu, Zhao, Yanqiu, Zhou, Ming, Zhang, Weidong, Zhang, Yu, Wan, Yixin, Li, Wenting, Song, Weifeng, Wang, Zhongmin Maxwell, Li, Baiyong, Xia, Michelle, Yang, Yunpeng, Fang, Wenfeng, Huang, Yan, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430160/
https://www.ncbi.nlm.nih.gov/pubmed/37593227
http://dx.doi.org/10.1016/j.eclinm.2023.102106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430160/
https://www.ncbi.nlm.nih.gov/pubmed/37593227
http://dx.doi.org/10.1016/j.eclinm.2023.102106

Ejemplares similares